These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20117004)

  • 1. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
    Mologni L; Rostagno R; Brussolo S; Knowles PP; Kjaer S; Murray-Rust J; Rosso E; Zambon A; Scapozza L; McDonald NQ; Lucchini V; Gambacorti-Passerini C
    Bioorg Med Chem; 2010 Feb; 18(4):1482-96. PubMed ID: 20117004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
    Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
    Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
    J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.
    Guo J; Zhao F; Yin W; Zhu M; Hao C; Pang Y; Wu T; Wang J; Zhao D; Li H; Cheng M
    Eur J Med Chem; 2018 Jul; 155():197-209. PubMed ID: 29886323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
    Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
    J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and chemical inhibition of the RET tyrosine kinase domain.
    Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
    J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
    Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
    J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 3-(substituted-benzylidene)-1,3-dihydro-indolin derivatives as human protein kinase CK2 and p60(c-Src) tyrosine kinase inhibitors.
    Olgen S; Götz C; Jose J
    Biol Pharm Bull; 2007 Apr; 30(4):715-8. PubMed ID: 17409508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkyne-linked 2,2-disubstituted-indolin-3-one oligomers as extended beta-strand mimetics.
    Wyrembak PN; Hamilton AD
    J Am Chem Soc; 2009 Apr; 131(13):4566-7. PubMed ID: 19284758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies.
    Olgen S; Akaho E; Nebioglu D
    Farmaco; 2005; 60(6-7):497-506. PubMed ID: 15927182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.
    Shehata MA; Contreras J; Martín-Hurtado A; Froux A; Mohamed HT; El-Sherif AA; Plaza-Menacho I
    J Adv Res; 2023 Mar; 45():87-100. PubMed ID: 35595215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
    Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of RET kinase inhibitors for targeted cancer therapy.
    Mologni L
    Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and receptor binding assay of indolin-2-one derivatives as dopamine D4 receptor ligands.
    Li GC; Zhang BL; Xia JY; Fang ZJ
    Pharmazie; 2015 Aug; 70(8):511-4. PubMed ID: 26380519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.